* If you want to update the article please login/register
The study will recruit approximately 55 people with amyloid-positive Mild Cognitive Impairment or AD. Each subject will then have 5-7 baseline visits, including neuropsychological testing, tACS-EEG analysis, TMS-EEG plasticity analysis, functional magnetic resonance imaging, blood and saliva sample collection, and optional lumbar puncture, if one is not available or it has been greater than six months, tau PET imaging, tau PET imaging, tau PET imaging, amyloid Positron Emission Tomography imaging, tMS-EEG calibration, amyloid Positron Emission Tomographe a e ratt a ae if one or it hash, amyloid Posiae tACS-EEG plasticity measurement, TMS-EEG plasticity analysis, amy characterization, and optional lumbar puncture characterization, and characterization, and amyloid Posiae characterization, or it has been greater than six months, tomics-EEG plasticity measurement, amyloid Positron Emission Tomography tACS-EEG plasticity measurement, amyloid Positron Emission Tomography scan, amyloid Positron Emission Tomography t Subjects will be tested for any side effects before and after each session and complete a short memory and reasoning questionnaire whether daily or weekly. At the conclusion of the daily sessions, 5-7 follow-up visits will include a repeat of the baseline findings, including amyloid and tau PET scans. The PET imaging studies will be carried out at Massachusetts General Hospital.
Source link: https://clinicaltrials.gov/ct2/show/NCT03880240
We have recently found an Asian woman with autoantibodies to interferon gamma, all of whom were diagnosed by non-tuberculous mycobacterial infections. Similar patient populations have been reported from Thailand, and we have discovered identical autoantibodies in anonymous serum samples from there. In addition, many of the Thai patients who have disseminated or lymphatic nontuberculous infections also had other opportunistic infections, such as salmonella, penicilliosis, and histoplasmosis. To determine the presence of autoantibodies to cytokines and to determine potential immunogenetic factors contributing to this disease's development, we recommend enrolling patients in a natural history study of non-HiV opportunistic infections to determine the relationship of autoantibodies to cytokines. This research will accrue up to 265 patients in the first five years as a result of the protocol, sample size justification, and the countries listed in the study.
Source link: https://clinicaltrials.gov/ct2/show/NCT00814827
This research seeks to explore the safety, tolerability, and efficacy of gamma-tACS in patients with the behavioral variant -FTD, demonstrating tACS potential mechanisms of action, target participation, and thus aiding in the design of larger clinical trials. Participants have met all inclusion and exclusion criteria, and they will be randomly assigned to either 6 weeks of daily Sham tACS sessions or 6 weeks of daily Sham tACS sessions. tACS is a method of stimulating the brain externally by using poor electric currents. With a special dye that is absorbed into your body, you can get a glimpse of your brain using a method of photographing your brain. In this research, the dye would help us to determine the glucose uptake in your brain. TMS is a noninvasive way of stimulating the brain, and it will be used in this research to determine your brain's plasticity. Brain plasticity is the brain's ability to change and learn by experience. TMS is caused by changes in the brain's electrical activity by a magnetic field. A coil that is held next to your scalp creates the magnetic field. Before and after the tACS treatment, we'll see how your brain responds to the TMS. To determine the brain's electrical activity, EEG is used in routine clinical care. Except for PET imaging, the investigators will recruit a sample of 20 age-matched healthy controls, who will be subjected to laboratory tests similar to the bv-FTD baseline study. The tACS intervention will not be available in healthy patients.
Source link: https://clinicaltrials.gov/ct2/show/NCT04425148
Improved clinical outcomes have resulted thanks to GammaTile therapy, but the results are limited to a limited number of patients, only 12 of whom were patients with metastatic brain tumors. Following metastatic tumor resection, the current standard of care, this randomized, controlled trial seeks to compare the efficacy and safety of intraoperative radiation therapy using GammaTilesTM versus SRS 3-4 weeks. Following the standard of care guideline, the surgical bed will be treated with adjunct radiation after the index lesion resection. Given these benefits, the rationale for doing this randomized control comparison study is to obtain additional data to support the use of this new FDA-cleared method of administering radiation therapy in the setting of newly diagnosed brain metastases.
Source link: https://clinicaltrials.gov/ct2/show/NCT04365374
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions